

# Loperamide Therapy for Voluminous Diarrhea in Ebola Virus Disease

Daniel S. Chertow,<sup>1</sup> Timothy M. Uyeki,<sup>2</sup> and Herbert L. DuPont<sup>3</sup>

<sup>1</sup>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland; <sup>2</sup>Centers for Disease Control and Prevention, Atlanta, Georgia; and <sup>3</sup>Center for Infectious Disease, University of Texas School of Public Health at Houston

**Keywords.** Ebola; loperamide; diarrhea; gastrointestinal losses; hypovolemia.

The number of cases of Ebola virus disease (EVD) in West Africa has surpassed 19 000 [1]. Efforts to identify, isolate, and provide medical care to patients with EVD are ongoing, and efforts to improve clinical care must focus on improved management of massive gastrointestinal fluid loss. Gastrointestinal fluid losses, largely through diarrhea, are a hallmark manifestation of EVD that contribute to hypovolemic shock, severe electrolyte abnormalities, and high mortality [2, 3]. In contrast to cholera toxin-mediated diarrheal losses, in which oral rehydration solution alone dramatically reduces mortality [4], oral rehydration for patients with EVD is often insufficient to accomplish resuscitation or repletion of ongoing fluid losses. However, EVD is a systemic viral illness with profound and debilitating manifestations, including high fever, asthenia, myalgia, and delirium, that limit self-directed oral rehydration. New strategies are needed to limit mortality related to cholera-like gastrointestinal fluid losses in EVD.

Massive gastrointestinal fluid and electrolyte losses may be successfully managed in resource-rich settings through careful estimation of volume losses, close laboratory monitoring of electrolytes and organ function, and replacement of fluid losses through balanced intravenous infusions over the course of illness [3]. This same level of intensive monitoring and care cannot be achieved in most EVD treatment units in West Africa, where high case loads, staffing shortages, and limited time in personal protective equipment because of the risk of heat exposure prohibit extended patient care interactions. In this setting, administration of antidiarrheal agents to limit gastrointestinal fluid and electrolyte losses may provide “a solution that prevents the problem at its source”. However, use of antidiarrheal agents for the management of EVD-mediated diarrhea is infrequently reported, and no safety and efficacy data to guide use in EVD exist.

Although the mechanism of EVD-mediated diarrhea has not yet been characterized, the large volume of watery stool suggests a secretory process. Tolerance of enteral feeding when gastrointestinal symptoms are adequately controlled suggests that the small intestine structure and function remain intact. Autopsy studies of patients with EVD who died show mild inflammation of small intestinal lamina propria, suggesting the possibility of an

inflammatory component to a secretory form of diarrhea, as well [5]. Clinically significant gastrointestinal bleeding observed in a small subset of patients with EVD, estimated to be <5% [2], raises the possibility that gastrointestinal inflammation may contribute to disease pathogenesis.

Loperamide is a potent antidiarrheal agent with antiperistaltic and antisecretory effects [6]. Reducing EVD diarrheal losses with loperamide might allow for correction of negative fluid balance, reduce hypovolemic shock, limit electrolyte losses, and consequently improve survival. Recently, one author (D. S. C.) and colleagues reported that oral antiemetics and antidiarrheal therapy improved symptoms and reduced gastrointestinal fluid loss and environmental contamination in patients with EVD [2]. The reduction in environmental contamination may also lower the risk of nosocomial transmission to healthcare personnel and other patients under evaluation.

There are limited data on the use of loperamide for EVD-mediated diarrhea [2]. Reluctance to use loperamide for EVD-mediated diarrhea may be based on the perception that it is of no benefit for the secretory diarrhea observed in cholera or concern about the risk of toxic megacolon when used to treat some bacterial inflammatory causes of diarrhea, such as *Clostridium difficile* infection [7]. Animal and human studies of shigellosis in the 1960s and subsequent case reports

Received 30 December 2014; accepted 5 January 2015; electronically published 8 January 2015.

Correspondence: Daniel S. Chertow, MD, MPH, Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Dr, 2C-145, Bethesda, MD 20892-1662 (chertowd@cc.nih.gov).

**The Journal of Infectious Diseases**® 2015;211:1036–7  
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.  
DOI: 10.1093/infdis/jiv001

of adverse events raised concern that antimotility drug use in patients with infectious diarrhea might contribute to a worse outcome [8]. However, multiple randomized, placebo-controlled, double-blinded trials of loperamide in combination with antibiotic therapy for management of infectious diarrhea in adults have demonstrated its safety and efficacy [9]. A meta-analysis of 13 clinical trials of loperamide use in children aged  $\leq 12$  years with infectious diarrhea and predominantly mild dehydration demonstrated a decrease in the duration and frequency of diarrhea [10]. Serious adverse events associated with loperamide use, including death, ileus, or lethargy, were reported only in children  $< 3$  years of age.

The Food and Drug Administration does not recommend loperamide use in children  $< 24$  months of age, and use is contraindicated in patients with dysentery (ie, stool with mucus or blood), but it may be used in combination with antibiotic treatment [11]. Loperamide should not be given to patients with suspected or documented ileus or intestinal paresis. Use of loperamide in patients with EVD to control gastrointestinal fluid losses

and reduce environmental contamination appears rational, based on existing clinical observations and the available published data. However, controlled clinical trials of loperamide treatment of diarrhea in patients with EVD, in combination with oral rehydration solution, to assess safety and efficacy in adults and children, including its possible impact upon improving survival, are urgently needed. Until strategies to improve management of gastrointestinal fluid and electrolyte losses are refined and widely implemented in the management of EVD in West Africa, the presently observed high case-fatality will persist.

### Notes

**Disclaimer.** This work represents the views of the authors and not necessarily the official policy of the Centers for Disease Control and Prevention or the National Institutes of Health.

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

1. World Health Organization. Ebola situation report. [http://www.who.int/csr/disease/](http://www.who.int/csr/disease/ebola/situation-reports/en)

- ebola/situation-reports/en. Accessed 5 January 2015.
2. Chertow DS, Kleine C, Edwards JK. Ebola virus disease in West Africa—clinical manifestations and management. *N Engl J Med* **2014**; 371:2054–7.
3. Lyon DM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. *N Engl J Med* **2014**; 371:2402–9.
4. Harris JB, LaRocque RC, Qadri F, et al. Cholera. *Lancet* **2012**; 379:2466–76.
5. Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. *J Pathol* **2014**; 235:153–74.
6. Baker DE. Loperamide: a pharmacological review. *Rev Gastroenterol Disord* **2007**; 7:S11–8.
7. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of *Clostridium difficile* diarrhea and colitis. *Clin Infect Dis* **2009**; 48:598–605.
8. DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. *JAMA* **1973**; 226:1525–8.
9. Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. *Clin Infect Dis* **2008**; 47:1007–14.
10. Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. *PLoS Med* **2007**; 4:e98.
11. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. *Ann Intern Med* **1993**; 118:582–6.